

CURRICULUM VITAE**1. ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ**

Όνομα: ΓΕΩΡΓΙΟΣ
Επίθετο: ΚΟΛΙΟΣ
Όνομα Πατρός: ΧΡΗΣΤΟΣ
Ημερομηνία γεννήσεως: 05.05.1955
Υπηκοότητα: Ελληνική
Διεύθυνση: Τμήμα Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης
Δραγάνα, Αλεξανδρούπολη, 68100
Τηλ./FAX: +3025510-30368
E-mail: gkolios@med.duth.gr
Website: <http://utopia.duth.gr/gkolios>

2. ΠΑΡΟΥΣΕΣ ΘΕΣΕΙΣ

- i) Καθηγητής Φαρμακολογίας, Τμήμα Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης (Ιούνιος 2008 - σήμερα).
- ii) Διευθυντής του Εργαστηρίου Φαρμακολογίας του Τμήματος Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης (Σεπτέμβριος 2008- σήμερα).
- iii) Διευθυντής του Εργαστηρίου Κλινικής Φαρμακολογίας του Πανεπιστημιακού Γενικού Νοσοκομείου Αλεξανδρούπολης (Σεπτέμβριος 2008- σήμερα).
- iv) Διευθυντής Μεταπτυχιακού Προγράμματος «Κλινική Φαρμακολογία-Θεραπευτική», Τμήμα Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης (Σεπτέμβριος 2009 - σήμερα).
- v) Αναπληρωτής Πρόεδρος, Τμήμα Ιατρικής, Δημοκρίτειο Πανεπιστήμιο Θράκης (Σεπτέμβριος 2013 - σήμερα).

3. ΠΑΝΕΠΙΣΤΗΜΙΑΚΕΣ ΣΠΟΥΔΕΣ

1973-1980 Ιατρική Σχολή Πανεπιστημίου Αθηνών, Πτυχίο Ιατρικής, Μάρτιος 1980.

4. ΜΕΤΑΠΤΥΧΙΑΚΟΙ ΤΙΤΛΟΙ

- i) Τίτλος Ιατρικής Ειδικότητας Γαστρεντερολογίας, Μάιος 1990
- ii) Διδακτορική Διατριβή, Ιατρική Σχολή Πανεπιστημίου Αθηνών, Μάιος 1992.
- iii) Διδακτορική Διατριβή (Doctor of Philosophy, PhD in Pharmacology), Σχολή Φαρμακολογίας, Πανεπιστήμιο του Bath, Αγγλία, Φεβρουάριος 1998.

5. ΘΕΣΕΙΣ ΣΤΗΝ ΕΛΛΑΔΑ

- i) Ειδικευόμενος στην Παθολογία, Β' Παθολογική Κλινική του 401 Γεν. Στρατιωτικού Νοσοκομείου Αθηνών, Αύγουστος 1981 – Οκτώβριος 1982.
- ii) Αγροτικός Ιατρός, Κέντρο Υγείας Βουργαρελίου Άρτα, Νοέμβριος 1982- Οκτώβριος 1984.
- iii) Ειδικευόμενος στην Παθολογία, Β' Παθολογική Κλινική του Σισμανογλείου Γενικού Νοσοκομείου Αθηνών, Φεβρουάριος 1985 – Φεβρουάριος 1986.
- iv) Ειδικευόμενος στην Γαστρεντερολογία, Β' Παθολογική Κλινική του Πανεπιστημίου Αθηνών, Ιπποκράτειο Γενικό Νοσοκομείο, Απρίλιος 1986 – Μάρτιος 1990.
- v) Επιμελητής Β' Γαστρεντερολογικό Τμήμα, Ιπποκράτειο Γενικό Νοσοκομείο Αθηνών, Μάιος 1991 – Δεκέμβριος 1997.
- vi) Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστημίου Κρήτης, Μάρτιος 2001 – Μάρτιος 2005.
- vii) Μόνιμος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστημίου Κρήτης, Μάρτιος 2005 – Ιούνιος 2008.
- viii) Μέλος του Επιστημονικού Συμβουλίου Εγκρίσεων, Α' ΕΣΕ, Εθνικού Οργανισμού Φαρμάκων, (Σεπτέμβριος 2008 - Νοέμβριος 2013).

6. ΘΕΣΕΙΣ ΣΤΟ ΕΞΩΤΕΡΙΚΟ

- i) Registrar Gastroenterologist, Royal United Hospital, Bath, England, (Ιούνιος 1990 – Ιούλιος 1991).
- ii) Research Fellow (Grade II), Department of Pharmacy and Pharmacology, University of Bath, UK, (Δεκέμβριος 1995 – Μάιος 1996)
- iii) Consultant Gastroenterologist, Royal United Hospital, Bath, England, (Ιανουάριος 1998 – Δεκέμβριος 2000).
- iv) Senior Clinical Research Fellow, Department of Pharmacy and Pharmacology, University of Bath, UK (Ιανουάριος 1998 – Δεκέμβριος 2000).
- v) Researcher, Novartis Pharmaceuticals Ltd United Kingdom, (Ιούνιος 1999 – Νοέμβριος 2000).
- vi) Visiting Professor, Department of Pharmacy and Pharmacology, University of Bath, UK (Ιανουάριος 2001 – σήμερα).
- vii) Visiting Scientist (Sabbatical), Laboratory of Molecular Immunology, Mucosal Immunobiology Section, National Institute of Health (NIH), Bethesda, Maryland, U.S.A. (Ιανουάριος 2007-Νοέμβριος 2007).
- viii) Visiting Scientist (Sabbatical), Immunology Institute, Mount Sinai School of Medicine, U.S.A. (Νοέμβριος 2007-Φεβρουάριος 2008).

7. ΣΥΜΜΕΤΟΧΗ ΣΕ ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΕΤΑΙΡΕΙΕΣ:

- i) Μέλος της Ελληνικής Γαστρεντερολογικής Εταιρείας (November 1990).
- ii) Μέλος της British Society for Immunology (November 1998).
- iii) Μέλος της European Society of Gastrointestinal and Abdominal Radiology (May 2005).
- iv) Μέλος της Society for Mucosal Immunology (September 2007).
- v) Μέλος της European Crohn's and Colitis Organization (May 2008).
- vi) Μέλος της Ελληνικής Φαρμακολογικής Εταιρείας (Φεβρουάριος 2009).
- vii) Μέλος της Επιστημονική Εταιρεία Σπανίων Παθήσεων & Ορφανών Φαρμάκων (Ιούλιος 2011)

8. ΕΡΕΥΝΗΤΙΚΕΣ ΧΡΗΜΑΤΟΔΟΤΗΣΕΙΣ

1. Chemokine production by human colonic epithelial cells in inflammatory bowel disease (National Association for Crohn and Colitis, UK 1994; £ 35.000).
2. Chemokine expression in the mucosa of inflammatory bowel disease patients; modulation by T-cell derived cytokines (Υποτροφία Ελληνικής Γαστρεντερολογικής Εταιρείας 1995; 3.000.000 Δρχ)
3. Mechanisms of mucosal injury in inflammatory bowel disease (Astra Foundation, UK 1996; £55.000).
4. Regulation of chemokines and inducible nitric oxide synthase by cytokines in Inflammatory Bowel Disease (Astra Foundation, UK 1997; £55,000).
5. The role of chemokines in the fibrotic process in inflammatory bowel disease (Novartis, UK 1999; £ 120.000)
6. Investigate the cross-talk between colonic epithelial cells, intraepithelial lymphocytes and myofibroblasts and its relevance to inflammatory bowel disease. (Wellcome Trust, UK 2002; £ 15.000).
7. Πρόγραμμα ΠΥΘΑΓΟΡΑΣ II: «Η επίδραση των χημειοκινών στη διεργασία της ίνωσης στη νόσο του Crohn. Ο ρόλος των μυοϊνοβλαστών» (Κ.Α 2094, 45200 ευρώ, Ιούνιος 2005).
8. Ο ρυθμιστικός ρόλος των αγγειογενετικών και αγγειοστατικών C-X-C χημειοκινών στον καρκίνο του παχέος εντέρου. Παράγοντες ρύθμισης της αύξησης και των μεταστάσεων του όγκου. (Υπουργείο Υγείας και πρόνοιας 12.000 ευρώ, 2006-2008).

9. Διαταραχές της έκφραση των υποδοχέων των χημειοκινών στην ιδιοπαθή πνευμονική ίνωση και την πνευμονική υπέρταση. Σε συνεργασία με τον Καθηγητή κ. Δημοσθένη Μπούρο (GlaxoSmithKline, Greece, 75,000 ευρώ, 2009-2012).
10. Δημιουργία Βιοτράπεζας στο δίκτυο "BBMRI -GR: Η Ελληνική Ερευνητική Υποδομή για τη δημιουργία Δικτύου Ελληνικών Βιοτραπεζών " (Εθνικό Στρατηγικό Πλαίσιο Αναφοράς ΕΣΠΑ 2014-2015: €95,000).

9. ΣΥΜΜΕΤΟΧΗ ΣΕ ΣΥΝΤΑΚΤΙΚΕΣ ΕΠΙΤΡΟΠΕΣ ΠΕΡΙΟΔΙΚΩΝ

1. Annals of Gastroenterology, Associate Editor
2. Clinical Medicine Reviews in Therapeutics, Editorial Board
3. European Journal of Pharmacology, Editorial Board
4. Global Journal of Stem Cell Biology and Transplantation, Editorial Board
5. Journal of Medical Case Reports, Editorial Board

10. ΕΠΙΛΕΓΜΕΝΕΣ ΔΗΜΟΣΙΕΥΣΕΙΣ (Pubmed):

- 1) **Kolios G**, Brown Z, Robson RL, Robertson DAF, Westwick J. Inducible nitric oxide synthase activity and expression in a human colonic epithelial cell line, HT-29. *British Journal of Pharmacology* 1995; 116:2866-2872.
- 2) **Kolios G**, Kaloterakis A, Filiotou A, Nakos A, Hadziyannis S. Gastroscopic findings in Mediterranean Kaposi's sarcoma (non-AIDS). *Gastrointestinal Endoscopy* 1995; 42:336-339.
- 3) **Kolios G**, Robertson DAF, Jordan NJ, Minty A, Caput D, Ferrara P, Westwick J. Interleukin-8 production by the human colon epithelial cell line HT-29: Modulation by interleukin -13. *British Journal of Pharmacology* 1996; 119:351-359.
- 4) Wright K, Ward SG, **Kolios G**, Westwick J. Activation of phosphatidylinositol 3-kinase by interleukin-13. An inhibitory signal for inducible nitric-oxide synthase expression in epithelial cell line HT-29. *Journal of Biological Chemistry* 1997; 272:12626-12633.
- 5) Davis AJ, **Kolios G**, Alveyn CG, Robertson DA. Antibiotic prophylaxis for ERCP: a comparison of oral ciprofloxacin with intravenous cephalosporin in the prophylaxis of high-risk patients. *Alimentary Pharmacology and Therapeutics* 1998; 12:207-211.
- 6) **Kolios G**, Rooney N, Murphy CT, Robertson DAF, Westwick J. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: Modulation by T-lymphocyte derived cytokines. *Gut* 1998; 43:56-63.
- 7) **Kolios G**, Petoumenos C, Nakos A. Mediators of inflammation: production and implication in inflammatory bowel disease. *Hepatogastroenterology* 1998; 45:1601-1609.
- 8) Jordan NJ, **Kolios G**, Abbot SE, Sinai MA, Thompson DA, Petraki K, Westwick J. Expression of functional CXCR4 chemokine receptors on human colonic epithelial cells. *Journal of Clinical Investigation* 1999; 104:1061-1069.
- 9) **Kolios G**, Wright KL, Jordan NJ, Leithead BJ, Robertson DAF, Westwick J. C-X-C and C-C chemokine expression and secretion by the human colonic epithelial cell line, HT-29: Differential effect of T-lymphocyte derived cytokines. *European Journal of Immunology* 1999; 29:530-536.
- 10) Wright K, **Kolios G**, Westwick J, Ward SG. Cytokine-induced apoptosis in epithelial HT-29 cells is independent of nitric oxide formation. Evidence for an interleukin-13-driven phosphatidylinositol 3-kinase-dependent survival mechanism. *Journal of Biological Chemistry* 1999; 274:17193-17201.
- 11) **Kolios G**, Wright KL, Linehan JD, Robertson DA, Westwick J. Interleukin-13 inhibits nitric oxide production in human colonic mucosa. *Hepatogastroenterology* 2000; 47:714-717.
- 12) Weaver SA, Russo MP, Wright KL, **Kolios G**, Jobin C, Robertson DA, Ward SG. Regulatory role of phosphatidylinositol 3-kinase on TNF-alpha-induced cyclooxygenase 2 expression in colonic epithelial cells. *Gastroenterology* 2001; 120:1117-1127.

- 13) **Kolios G**, Valatas V, Psilopoulos D, Petraki K, Kouroumalis E. Depletion of non specific esterase activity in the colonic mucosa of patients with ulcerative colitis. *European Journal of Clinical Investigation* 2002; 32:265-273.
- 14) Valatas V, Xidakis C, Roumpaki H, **Kolios G**, Kouroumalis EA. Isolation of rat Kupffer cells: a combined methodology for highly purified primary cultures. *Cell Biology International* 2003; 27:67-73.
- 15) Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. *Immunology* 2004; 113:427-437.
- 16) Koutroubakis IE, Theodoropoulou A, Xidakis C, Sfiridaki A, Notas G, **Kolios G**, Kouroumalis EA. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. *European Journal of Gastroenterology and Hepatology* 2004; 16:1147-1152.
- 17) Notas G, **Kolios G**, Mastrodimou N, Kampa M, Vasilaki A, Xidakis C, Castanas E, Thermos K, Kouroumalis E. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors. *Journal of Hepatology* 2004; 40:792-798.
- 18) Valatas V, **Kolios G**, Manousou P, Notas G, Xidakis C, Diamantis I, Kouroumalis E. Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells. *British Journal of Pharmacology* 2004; 141:477-487.
- 19) Valatas V, **Kolios G**, Manousou P, Xidakis C, Notas G, Ljumovic D, Kouroumalis EA. Secretion of inflammatory mediators by isolated rat Kupffer cells: the effect of octreotide. *Regulatory Peptides* 2004; 120:215-225.
- 20) Vasilaki A, Papadaki T, Notas G, **Kolios G**, Mastrodimou N, Hoyer D, Tsilimbaris M, Kouroumalis E, Pallikaris I, Thermos K. Effect of somatostatin on nitric oxide production in human retinal pigment epithelium cell cultures. *Investigative Ophthalmology & Visual Science* 2004; 45:1499-1506.
- 21) Wright KL, Weaver SA, Patel K, Coopman K, Feeney M, **Kolios G**, Robertson DA, Ward SG. Differential regulation of prostaglandin E biosynthesis by interferon-gamma in colonic epithelial cells. *British Journal of Pharmacology* 2004; 141:1091-1097.
- 22) Xidakis C, **Kolios G**, Valatas V, Notas G, Mouzas I, Kouroumalis E. Effect of octreotide on apoptosis-related proteins in rat Kupffer cells: a possible anti-tumour mechanism. *Anticancer Research* 2004; 24:833-841.
- 23) Linehan JD, **Kolios G**, Valatas V, Robertson DA, Westwick J. Effect of corticosteroids on nitric oxide production in inflammatory bowel disease: are leukocytes the site of action? *American Journal Physiology - Gastrointestinal & Liver Physiology* 2005; 288:G261-G267.
- 24) Dimoulios P, **Kolios G**, Notas G, Matrella E, Xidakis C, Koulentaki M, Tsagarakis N, Kouroumalis A, Kouroumalis E. Ursodeoxycholic acid reduces increased circulating endothelin 2 in primary biliary cirrhosis. *Alimentary Pharmacology and Therapeutics* 2005; 21:227-234.
- 25) Xidakis C, Ljumovic D, Manousou P, Notas G, Valatas V, **Kolios G**, Kouroumalis E. Production of pro- and anti-fibrotic agents by rat Kupffer cells; the effect of octreotide. *Digestive Diseases and Sciences* 2005; 50:935-941.
- 26) Kouroumalis A, Nibbs RJ, Aptel H, Wright KL, **Kolios G**, Ward SG. The Chemokines CXCL9, CXCL10, and CXCL11 Differentially Stimulate G α i-Independent Signaling and Actin Responses in Human Intestinal Myofibroblasts. *Journal of Immunology* 2005; 175:5403-5411.
- 27) Linehan JD, **Kolios G**, Valatas V, Robertson DA, Westwick J. Immunomodulatory cytokines suppress epithelial nitric oxide production in inflammatory bowel disease by acting on mononuclear cells. *Free Radical Biology & Medicine* 2005; 39:1560-1569.

- 28) Charalampopoulos I, Androulidaki A, Minas V, Chatzaki E, Tsatsanis C, Notas G, Xidakis C, **Kolios G**, Kouroumalis E, Margioris AN, Gravanis A. Neuropeptide urocortin and its receptors are expressed in rat kupffer cells. *Neuroendocrinology* 2006; 84:49-57.
- 29) **Kolios G**, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. *World Journal of Gastroenterology* 2006; 12:7413-7420.
- 30) **Kolios G**, Manousou P, Bourikas L, Notas G, Tsagarakis N, Mouzas I, Kouroumalis E. Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium. *European Journal of Clinical Investigation* 2006; 36:720-729.
- 31) **Kolios G**, Kotzampassi K, Manousou P, Paramythiotis D, Papanastasiou H, Drygiannakis I, Notas G, Tsagarakis N, Eleftheriadis E, Kouroumalis E. Enteral nutrition affects nitric oxide production in peripheral blood and liver after a postoperative lipopolysaccharide-induced endotoxemia in rats. *Nutrition* 2007; 23:575-581.
- 32) Xidakis C, Mastrodimou N, Notas G, Renieri E, **Kolios G**, Kouroumalis E, Thermos K. RT-PCR and immunocytochemistry studies support the presence of somatostatin, cortistatin and somatostatin receptor subtypes in rat Kupffer cells. *Regulatory Peptides* 2007; 143:76-82.
- 33) Damaskos D, **Kolios G**. Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. *British Journal of Clinical Pharmacology* 2008; 65:453-467.
- 34) **Kolios G**, Valatas V, Manousou P, Xidakis C, Notas G, Kouroumalis E. Nitric oxide and MCP-1 regulation in LPS activated rat Kupffer cells. *Molecular and Cellular Biochemistry* 2008; 319:91-98.
- 35) Manousou P, **Kolios G**, Drygiannakis I, Pyrovolaki K, Bourikas L, Papadaki HA, Kouroumalis E. Expression of a splice variant of CXCR3 in Crohn's disease patients; indication for a lymphocyte-epithelial cell interaction. *Journal of Gastroenterology and Hepatology* 2008; 23:1823-1833.
- 36) Bourikas LA, **Kolios G**, Valatas V, Notas G, Drygiannakis I, Pelagiadis I, Manousou P, Klironomos S, Mouzas IA, Kouroumalis E. Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. *British Journal of Pharmacology* 2009; 157:362-370.
- 37) Galazios G, Papazoglou D, Tsikouras P, **Kolios G**. Vascular endothelial growth factor gene polymorphisms and pregnancy. *Journal of Maternal-Fetal & Neonatal Medicine* 2009; 22:371-378.
- 38) Kotzampassi K, **Kolios G**, Manousou P, Kazamias P, Paramythiotis D, Papavramidis TS, Heliadis S, Kouroumalis E, Eleftheriadis E. Oxidative stress due to anesthesia and surgical trauma: Importance of early enteral nutrition. *Molecular Nutrition & Food Research* 2009; 53:770-779.
- 39) Paschos KA, **Kolios G**, Chatzaki E. The corticotropin-releasing factor system in inflammatory bowel disease: Prospects for new therapeutic approaches. *Drug Discovery Today* 2009; 14:713-720.
- 40) Kefalakes E, Stylianides TJ, Amanakis G, **Kolios G**. Exacerbation of Inflammatory Bowel Diseases associated with the use of nonsteroidal anti-inflammatory drugs: Myth or Reality? *European Journal of Clinical Pharmacology* 2009; 65:963-70.
- 41) Tsagarakis NJ, Drygiannakis I, Batistakis AG, **Kolios G**, Kouroumalis EA. A concentration dependent effect of Ursodeoxycholate on apoptosis and caspases activities of HepG2 hepatocellular carcinoma cells. *European Journal of Pharmacology* 2010; 640: 1-7.
- 42) Manousou P, **Kolios G**, Valatas V, Drygiannakis I, Bourikas L, Pyrovolaki K, Koutroubakis I, Papadaki HA, Kouroumalis E. Increased expression of Chemokine receptor CCR3 and its ligands in ulcerative colitis; the role of colonic epithelial cells in in vitro studies. *Clinical & Experimental Immunology* 2010; 162: 337-347.
- 43) Kapetanakis S, Drygiannakis I, Kazakos K, Papanas N, **Kolios G**, Kouroumalis E, Verettas DA. Serum TGF- β 2 and TGF- β 3 are increased and positively correlated to pain, functionality and radiographic staging in osteoarthritis. *Orthopedics* 2010; 33:551.

- 44) Tsagarakis NJ, Drygiannakis I, Batistakis AG, **Kolios G**, Kouroumalis EA. Octreotide induces caspase activation and apoptosis in human hepatoma cells (HepG2). *World Journal of Gastroenterology*; 2011; 17:313-321.
- 45) Kambas K, Chrysanthopoulou A, Kourtzelis I, Skordala M, Mitroulis I, Rafail S, Vradelis S, Sigalas I, Wu YQ, Speletas S, **Kolios G**, Ritis K. Endothelin-1 signaling promotes fibrosis in vitro in a bronchopulmonary dysplasia model by activating the extrinsic coagulation cascade. *Journal of Immunology* 2011; 186:6568-6575.
- 46) Chrysanthopoulou A, Mitroulis I, Kambas K, Skendros P, Kourtzelis I, Vradelis S, **Kolios G**, Aslanidis S, Doumas M, Ritis K. Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through endothelin-1 receptor A up-regulation. *Arthritis & Rheumatism* 2011; 63:3586-3597.
- 47) Tzouveleki A, Bouros E, Oikonomou A, Ntoliou P, Zacharis G, **Kolios G**, Bouros D. Effect and safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis. *Pulmonary Medicine* 2011; 2011:849035.
- 48) Tzouveleki A, Koliakos G, Ntoliou P, Baira I, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, **Kolios G**, Paspaliaris V, Kakagia D, Kotsianidis I, Froudarakis M, Bouros D. Stem cell therapy for Idiopathic Pulmonary Fibrosis. A protocol proposal. *Journal of Translational Medicine* 2011; 9:182.
- 49) Tzouveleki A, Galanopoulos N, Bouros E, **Kolios G**, Zacharis G, Ntoliou P, Koulelidis A, Oikonomou A, Bouros D. Effect and safety of Mycophenolate mofetil or sodium in systemic sclerosis - associated interstitial lung disease. A meta-analysis. *Pulmonary Medicine* 2012; 2012:143637.
- 50) Domvri K, Zarogoulidis P, Porpodis K, Koffa M, Lambropoulou M, Kakolyris S, **Kolios G**, Zarogoulidis K, Chatzaki E. Gene therapy in liver diseases: State-of-the-art and future perspectives. *Current Gene Therapy* 2012; 12:463-483.
- 51) Drygiannakis I, Valatas V, Sfakianaki O, Bourikas L, Manousou P, Kambas K, Ritis K, **Kolios G**, Kouroumalis E. Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: implication in intestinal fibrosis. *Journal of Crohn's and Colitis* 2013; 7:286-300.
- 52) Valatas V, He J, Rivollier A, **Kolios G**, Kitamura K, Kelsall BL. Host-dependent control of early regulatory and effector T cell differentiation underlies the genetic susceptibility of RAG2-deficient mouse strains to transfer colitis. *Mucosal Immunology* 2013; 6:601-611.
- 53) **Kolios G**, Moodley Y. Introduction to Stem Cells and Regenerative Medicine. *Respiration* 2013; 85:3-10.
- 54) Manousou P, **Kolios G**, Drygiannakis I, Koulentaki M, Pyrovolaki K, Voumvouraki A, Notas G, Bourikas L, Papadaki HA, Kouroumalis E. CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid. *Clinical & Experimental Immunology* 2013; 172:9-15.
- 55) Chatzaki E, Anton PA, Million M, Lambropoulou M, Costantinidis T, **Kolios G**, Taché Y, Grigoriadis DE. CRF Receptor 2 in human colonic mucosa: down-regulation in Ulcerative Colitis. *World Journal of Gastroenterology* 2013; 19:1416-1423.
- 56) Pazaitou-Panayiotou K, Chemonidou C, Poupri A, Koureta M, Kaprara A, Lambropoulou M, Constantinidis TC, Galaktidou G, Koffa M, Kiziridou A, Kakolyris S, **Kolios G**, Kortsaris A, Chatzaki E. Gonadotropin-Releasing Hormone neuropeptides and receptor in human breast cancer: correlation to poor prognosis parameters. *Peptides* 2013; 42:15-24.
- 57) Balgouranidou I, Karayiannakis A, Matthaios D, Bolanaki H, Tripsianis G, Tentes AA, Lianidou E, Chatzaki E, Fiska A, Lambropoulou M, **Kolios G**, Kakolyris S. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. *Clinical Chemistry and Laboratory Medicine* 2013; 51:1505-1510.

- 58) Paschos KA, Chouridou E, Koureta M, Lambropoulou M, **Kolios G**, Chatzaki E. The Corticotropin Releasing Factor system in the liver: expression, actions and possible implications in hepatic physiology and pathology. *Hormones (Athens)* 2013; 12:236-245
- 59) Drosos I, **Kolios G**. Stem cells in liver regeneration and their potential clinical applications. *Stem Cell Reviews and Reports* 2013; 9:668-684.
- 60) Tzouveleakis A, Paspaliaris V, Koliakos G, Ntoliou P, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, Dardzinski B, Gritzalis D, Antoniadis A, Froudarakis M, **Kolios G**, Bouros D. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in Idiopathic Pulmonary Fibrosis. *Journal of Translational Medicine* 2013; 11:171.
- 61) Valatas V, Vakas M, **Kolios G**. The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. *American Journal of Physiology, Gastrointestinal Liver Physiology* 2013; 305:G763-G785.
- 62) Lalidou F, **Kolios G**, Drosos GI. Bone Infections and Bone Graft Substitutes for Local Antibiotic Therapy. *Surgical Technology International* 2014; 24:353-62.
- 63) Karampelas T, Argyros O, Sayyad N, Spyridaki K, Pappas C, Morgan K, **Kolios G**, Millar RP, Liapakis G, Tzakos AG, Fokas D, Tamvakopoulos C. GnRH-Gemcitabine Conjugates for the Treatment of Androgen-Independent Prostate Cancer: Pharmacokinetic Enhancements Combined with Targeted Drug Delivery *Bioconjugate Chemistry* 2014; 25:813-823.
- 64) Fouka E, Lamprianidou E, Arvanitidis K, Filidou E, **Kolios G**, Miltiades P, Paraskakis E, Antoniadis A, Kotsianidis I, Bouros D. Low-Dose Clarithromycin Therapy Modulates Th17 Response In Non-Cystic Fibrosis Bronchiectasis Patients. *Lung*. 2014; 192:849-55.
- 65) Lalidou F, **Kolios G**, Tavridou A, Drosos GI. Bone grafts as carriers for local antibiotic delivery for the treatment and prevention of bone infections. *Surgical Technology International* 2014; 25:239-45.
- 66) Drosos I, Tavridou A, **Kolios G**. New aspects on the metabolic role of intestinal microbiota in the development of atherosclerosis. *Metabolism-Clinical & Experimental* 2015; 64:476-481.
- 67) Valatas V, Bamias G, **Kolios G**. Experimental Colitis Models: Insights into the Pathogenesis of Inflammatory Bowel Disease and Translational Issues. *European Journal of Pharmacology* 2015; 759:253–264.
- 68) Sertaridou E, Papaioannou V, **Kolios G**, Pneumatikos I. Gut failure in critical care: old school versus new school. *Annals of Gastroenterology* 2015; 28:309-322.
- 69) Fotiadis K, Filidou E, Arvanitidis K, Vassilis Valatas V, Stavrou G, Basdanis G, Paspaliaris V, **Kolios G**, Kotzampassi K. Intraperitoneal application of phospholipids for the prevention of post-operative adhesions: a possible role of myofibroblasts. *Journal of Surgical Research* 2015; 197:291-300.
- 70) **Kolios G**. Bin1 Antibodies for IBD Therapy: Is Permeability the Answer BAR None? *Digestive Disease Science*. 2016;61:330-331.
- 71) **Kolios G**. Animal models of inflammatory bowel disease: how useful are they really? *Current Opinion Gastroenterology*. 2016;32:251-257.
- 72) Kotanidis L, Nikolettos K, Petousis S, Asimakopoulos B, Chatzimitrou E, **Kolios G**, Nikolettos N. The use of serum anti-Mullerian hormone (AMH) levels and antral follicle count (AFC) to predict the number of oocytes collected and availability of embryos for cryopreservation in IVF. *Journal of Endocrinological Investigation* 2016; 39:1459-1464.
- 73) Bamias G, Filidou E, Goukos D, Valatas V, Arvanitidis K, Panagopoulou M, Kouklakis G, Daikos G, Ladas SD, **Kolios G**. Crohn's Disease-Associated Mucosal Factors Regulate the Expression of TNF-like Cytokine 1A (TL1A) and its Receptors in Primary Subepithelial Intestinal Myofibroblasts and Intestinal Epithelial Cells. *Translational Research* 2017;180:118-130.

- 74) Panagopoulou M, Lambropoulou M, Balgkouranidou I, Nena E, Karaglani M, Nicolaidou C, Asimaki A, Konstantinidis T, Constantinidis TC, **Kolios G**, Kakolyris S, Agorastos T, Chatzaki E. Gene promoter methylation and protein expression of BRMS1 in uterine cervix in relation to high-risk human papilloma virus infection and cancer. *Tumor Biology* 2017; in press.
- 75) Valatas V, Filidou E, Drygianakis I, **Kolios G**. Stromal and Immune cells in Gut Fibrosis: the Myofibroblast and the Scarface. *Annals of Gastroenterology* 2017; in press.
- 76) Dovrolis N, **Kolios G**, Spyrou G, Maroulakou I. Laying in silico pipelines for drug repositioning; a paradigm in ensemble analysis for neurodegenerative diseases. *Drug Discovery Today* 2017; in press,

Μάρτιος 2017

Γεώργιος Κολιός, MD PhD